Gliklazyd MR. Spojrzenie wielodyscyplinarne Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2017
Słowa kluczowe:
cukrzyca typu 2, powikłania cukrzycy, hipoglikemia, gliklazyd MR
##plugins.themes.bootstrap3.article.main##
Abstrakt
Jedną z grup leków hipoglikemizujących, stosowaną od ponad 50 lat w leczeniu cukrzycy, są pochodne sulfonylomocznika. Tak długi okres używania pozwala na pełną ocenę ich właściwości i skuteczności klinicznej. Wśród leków tej grupy wyróżnia się gliklazyd MR, w formule, która pozwala na dawkowanie raz dziennie. Liczne badania przeprowadzone z użyciem gliklazydu MR wskazują, iż terapia nim jest efektywna w zakresie obniżania glikemii i bezpieczna w zakresie ryzyka hipoglikemii i powikłań cukrzycy. Stosowanie gliklazydu MR powinno być rozważane u każdego chorego nieskutecznie leczonego metforminą.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Strojek, K., Okopień, B., Bułdak, Łukasz, & Małecki , R. (2017). Gliklazyd MR. Spojrzenie wielodyscyplinarne . Medycyna Faktów , 10(3(36), 206-209. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2124
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Gæde P., Vedel P., Larsen N. et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 2003; 348: 383-393.
2. DeFronzo R.: From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus.
3. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2017. Stanowisko Polskiego Towarzystwa Diabetologicznego. Diabetologia Kliniczna 2017; 3: supl. A.
4. Gæde P., Oellgaard J., Carstensen B. et al.: Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia 2016; 59: 2298-2307.
5. Gregorio F., Ambrosi F., Cristallini S. et al.: Therapeutical concentrations of tolbutamide, glibenclamide, gliclazide and gliquidone at different glucose levels: in vitro effects on pancreatic A- and B-cell function. Diabetes Res. Clin. Pract. 1992; 18(3): 197-206.
6. Chan S.P., Colagiuri S.: Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents. Diabetes Res. Clin. Pract. 2015; 110(1): 75-81.
7. Proks P., Reimann F., Green N. et al.: Sulfonylurea stimulation of insulin secretion. Diabetes 2002; 51(supl. 3): S368-376.
8. Abdelmoneim A.S., Hasenbank S.E., Seubert J.M. et al.: Variations in tissue selectivity amongst insulin secretagogues: a systematic review. Diabetes Obes. Metab. 2012; 14(2): 130-138.
9. Ashcroft F.M., Gribble F.M.: Tissue-specific effects of sulfonylureas: lessons from studies of cloned K(ATP) channels. J. Diabetes Complications 2000; 14(4): 192-196.
10. Schernthaner G.: Gliclazide modified release: A critical review of pharmacodynamic, metabolic, and vasoprotective effects. Metabolism 2003; 52(8 supl. 1): 29-34.
11. Patel A.; ADVANCE Collaborative Group; MacMahon S., Chalmers J. et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840.
12. Levey A.S., Cattran D., Friedman A. et al.: Proteinuria as a surrogate outcome in CKD: report of a scientific workshopsponsored by the National Kidney Foundation and the US Food and Drug Administration. Am. J. Kidney Dis. 2009; 54: 205-226.
13. Lee Y.H., Lee C.J., Lee H.S. et al.: Comparing kidney outcomes in type 2 diabetes treated with different sulphonylureas in real-life clinical practice. Diabetes & Metabolism 2015; 41: 208-215.
14. Zoungas S., Chalmers J., Neal B. et al.; for the ADVANCE-ON Collaborative Group: Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N. Engl. Med. 2014; 371: 1392-1406.
15. Schernthaner G., Grimaldi A., Di Mario U.et al.: GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur. J. Clin. Invest. 2004; 34: 535-542.
16. Schramm T.K., Gislason G.H., Vaag A. et al.: Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur. Heart J. 2011; 32(15): 1900-1908.
2. DeFronzo R.: From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus.
3. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2017. Stanowisko Polskiego Towarzystwa Diabetologicznego. Diabetologia Kliniczna 2017; 3: supl. A.
4. Gæde P., Oellgaard J., Carstensen B. et al.: Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia 2016; 59: 2298-2307.
5. Gregorio F., Ambrosi F., Cristallini S. et al.: Therapeutical concentrations of tolbutamide, glibenclamide, gliclazide and gliquidone at different glucose levels: in vitro effects on pancreatic A- and B-cell function. Diabetes Res. Clin. Pract. 1992; 18(3): 197-206.
6. Chan S.P., Colagiuri S.: Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents. Diabetes Res. Clin. Pract. 2015; 110(1): 75-81.
7. Proks P., Reimann F., Green N. et al.: Sulfonylurea stimulation of insulin secretion. Diabetes 2002; 51(supl. 3): S368-376.
8. Abdelmoneim A.S., Hasenbank S.E., Seubert J.M. et al.: Variations in tissue selectivity amongst insulin secretagogues: a systematic review. Diabetes Obes. Metab. 2012; 14(2): 130-138.
9. Ashcroft F.M., Gribble F.M.: Tissue-specific effects of sulfonylureas: lessons from studies of cloned K(ATP) channels. J. Diabetes Complications 2000; 14(4): 192-196.
10. Schernthaner G.: Gliclazide modified release: A critical review of pharmacodynamic, metabolic, and vasoprotective effects. Metabolism 2003; 52(8 supl. 1): 29-34.
11. Patel A.; ADVANCE Collaborative Group; MacMahon S., Chalmers J. et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840.
12. Levey A.S., Cattran D., Friedman A. et al.: Proteinuria as a surrogate outcome in CKD: report of a scientific workshopsponsored by the National Kidney Foundation and the US Food and Drug Administration. Am. J. Kidney Dis. 2009; 54: 205-226.
13. Lee Y.H., Lee C.J., Lee H.S. et al.: Comparing kidney outcomes in type 2 diabetes treated with different sulphonylureas in real-life clinical practice. Diabetes & Metabolism 2015; 41: 208-215.
14. Zoungas S., Chalmers J., Neal B. et al.; for the ADVANCE-ON Collaborative Group: Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N. Engl. Med. 2014; 371: 1392-1406.
15. Schernthaner G., Grimaldi A., Di Mario U.et al.: GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur. J. Clin. Invest. 2004; 34: 535-542.
16. Schramm T.K., Gislason G.H., Vaag A. et al.: Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur. Heart J. 2011; 32(15): 1900-1908.